Skip to main content
ELDN
NASDAQ Life Sciences

Eledon Pharmaceuticals Exchanges Common Stock for Pre-Funded Warrants with Major Investor

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
7
Price
$1.62
Mkt Cap
$121.637M
52W Low
$1.35
52W High
$4.98
Market data snapshot near publication time

summarizeSummary

Eledon Pharmaceuticals entered an agreement to exchange 4.2 million common shares for pre-funded warrants with Coastlands Capital Partners LP, a move that temporarily reduces outstanding common stock and allows the investor to manage beneficial ownership.


check_boxKey Events

  • Exchange Agreement Executed

    Eledon Pharmaceuticals, Inc. entered into an exchange agreement with Coastlands Capital Partners LP on December 30, 2025.

  • Common Stock Exchanged for Warrants

    Coastlands Capital Partners LP exchanged 4,203,764 shares of common stock for pre-funded warrants to purchase an equal number of common shares.

  • Beneficial Ownership Management

    The pre-funded warrants include a beneficial ownership limitation, typically 4.99%, which can be increased to 19.99% with prior notice, allowing the holder to manage their reported ownership stake.

  • Pre-Funded Nature

    The warrants have a nominal exercise price of $0.001 per share, as the aggregate exercise price was pre-funded to the company prior to the initial exercise date.


auto_awesomeAnalysis

This transaction represents a strategic capital structure adjustment rather than a traditional capital raise or dilutive offering. Eledon Pharmaceuticals is effectively reducing its outstanding common share count by 4.2 million shares in exchange for pre-funded warrants. This could temporarily enhance per-share metrics. For Coastlands Capital Partners LP, this structure allows them to maintain a significant economic interest in the company while managing their beneficial ownership percentage, potentially staying below certain reporting thresholds. The 'pre-funded' nature indicates the company has already received the capital for these shares, and the warrants will eventually convert back to common stock at a nominal exercise price. Investors should note this reclassification of a substantial equity stake and its implications for capital structure and investor relations.

At the time of this filing, ELDN was trading at $1.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.6M. The 52-week trading range was $1.35 to $4.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ELDN - Latest Insights

ELDN
Apr 20, 2026, 5:45 PM EDT
Filing Type: PRE 14A
Importance Score:
9
ELDN
Mar 19, 2026, 5:05 PM EDT
Filing Type: 10-K
Importance Score:
7
ELDN
Mar 19, 2026, 5:02 PM EDT
Filing Type: 8-K
Importance Score:
8
ELDN
Mar 10, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
ELDN
Jan 02, 2026, 4:31 PM EST
Filing Type: 8-K
Importance Score:
7